Progress in OCU410 ArMaDa Study: Cohort 3 Enrollment & Phase 2 Initiation Granted
Friday, 31 May 2024, 09:48
OCU410 ArMaDa Study: Simultaneous Cohort 3 Enrollment & Phase 2 Initiation Approved
The Data and Safety Monitoring Board has given the green light for the simultaneous enrollment in Cohort 3 and the initiation of Phase 2 in the OCU410 ArMaDa study focused on Geographic Atrophy. This significant development marks a crucial milestone in advancing research and treatment for this condition, offering hope for patients affected. The approval underscores the potential effectiveness of OCU410 in addressing the challenges posed by Geographic Atrophy, signaling progress and opportunities within the study.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.